Difficulty: Medium
Average Score: 85%
Practice
Indicate the antipsychotic drug having a muscarinic-cholinergic blocking activity:
Correct answer
A
Rationale
In pharmacology, understanding the pharmacodynamic properties of drugs is crucial for safe and effective medication use. In this case, the correct answer is A) Chlorpromazine. Chlorpromazine is a typical antipsychotic drug known for its muscarinic-cholinergic blocking activity. This drug exerts its antipsychotic effects by blocking dopamine receptors in the brain, but it also has significant anticholinergic effects due to its muscarinic receptor blockade.
Option B) Clorprothixene is an antipsychotic drug, but it does not possess significant muscarinic-cholinergic blocking activity compared to chlorpromazine. Option C) Risperidone is an atypical antipsychotic with minimal anticholinergic effects. Option D) Haloperidol is another typical antipsychotic that lacks significant muscarinic-cholinergic blocking activity.
Understanding the pharmacological properties of antipsychotic drugs is essential for healthcare professionals to make informed decisions about drug selection based on the patient's needs and potential side effects. By knowing the specific receptor activities of each drug, healthcare providers can tailor treatment plans to optimize therapeutic outcomes while minimizing adverse effects.
Option B) Clorprothixene is an antipsychotic drug, but it does not possess significant muscarinic-cholinergic blocking activity compared to chlorpromazine. Option C) Risperidone is an atypical antipsychotic with minimal anticholinergic effects. Option D) Haloperidol is another typical antipsychotic that lacks significant muscarinic-cholinergic blocking activity.
Understanding the pharmacological properties of antipsychotic drugs is essential for healthcare professionals to make informed decisions about drug selection based on the patient's needs and potential side effects. By knowing the specific receptor activities of each drug, healthcare providers can tailor treatment plans to optimize therapeutic outcomes while minimizing adverse effects.